- Patent Title: Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
-
Application No.: US17279937Application Date: 2019-09-25
-
Publication No.: US11638730B2Publication Date: 2023-05-02
- Inventor: Shinsuke Nakao , Tatsuya Kawase
- Applicant: ASTELLAS PHARMA INC.
- Applicant Address: JP Tokyo
- Assignee: ASTELLAS PHARMA INC.
- Current Assignee: ASTELLAS PHARMA INC.
- Current Assignee Address: JP Tokyo
- Agency: Foley & Lardner LLP
- Priority: JPJP2018-179632 20180926
- International Application: PCT/JP2019/037448 WO 20190925
- International Announcement: WO2020/067085 WO 20200402
- Main IPC: A61K35/768
- IPC: A61K35/768 ; A61K38/20 ; A61K48/00 ; A61P35/00 ; A61P35/04 ; C12N15/24 ; A61K39/395 ; C12N7/00 ; A61K39/00
Abstract:
The present invention provides a combination therapy of genetically modified vaccinia virus (particularly oncolytic vaccinia virus) and another cancer therapy for use in treating cancer, and a pharmaceutical composition and a combination kit for use in the therapy. More specifically, the invention provides a therapy with vaccinia virus containing a polynucleotide encoding interleukin-7 (IL-7) and a polynucleotide encoding interleukin-12 (IL-12) in combination with an immune checkpoint inhibitor, and a pharmaceutical composition and a combination kit for use in the therapy.
Public/Granted literature
Information query
IPC分类:
